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A B S T R A C T
Background: Germline testing is recommended for all men with metastatic prostate cancer (PCa), and for some
with localized PCa meeting specific histologic or family history criteria. Germline genetic evaluation has im-
portant implications for PCa prognosis and management, as well as implications for family members and cancer
screening. Despite the importance of germline evaluation, its utilization in urologic practice is unknown.
Materials and Methods: We conducted a 32-item survey of U.S. urologists to examine knowledge of germline
testing guidelines and practice patterns. It was shared through email to 6 American Urological Association
sections, the Veterans Affairs Urology Mailgroup, and social media.
Results: Among 132 total respondents from diverse practice settings across the U.S., 12% perform germline
testing, 44% refer to a genetic counselor, 11% do both, and 33% do not test/refer. Only 4% had formal education
in genetics. While 98% ask about PCa family history, only 76% and 52% ask about breast and ovarian cancer.
When presented with hypothetical case scenarios where germline testing is indicated, many respondents in-
dicated they would not offer genetic counseling or testing. Younger age (p = 0,03), academic practice
(p = 0.04), and specializing in PCa/oncology (p = 0.007) were significantly associated with performing or
referring for germline testing. Specializing in PCa/oncology was significantly associated with recommending
germline testing for all case scenarios involving metastatic PCa (p = 0.0009)
Conclusion: Our results suggest significant gaps in knowledge of germline testing and alignment of practice with
national guidelines among urologists. Germline testing education and facilitation of genetic evaluation in ur-
ologic practice is warranted.
Clinical Practice Points
-Genetic testing has significant implications for patients with
prostate cancer and their families.
-Broad family history collection is very important for optimal
testing and genetic assessment.
-Genetic evaluation influences screening and treatment
decisions for prostate cancer.
Introduction
The past decade has witnessed rapid advances in genetic knowledge
and precision medicine. Current guidelines recommend germline
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testing for all patients with metastatic prostate cancer (PCa) [1,2].
Mutations in several genes are associated with PCa risk to varying de-
grees, including BRCA2, BRCA1, HOXB13, DNA mismatch repair genes,
and CHEK2. Furthermore, men with metastatic PCa have higher rates of
germline mutations, particularly in DNA repair genes [3,4]. Germline
testing is also recommended for select patients with localized disease
with specific histological features (such as intraductal or ductal his-
tology) or suspicious family cancer history (such as death from PCa,
young age of PCa diagnosis or death, or cancers associated with her-
editary breast and ovarian cancer or Lynch syndrome) [1,2]. As such,
germline testing guidelines have significantly expanded and have be-
come complex. To address this complexity, the international Philadel-
phia Prostate Cancer Consensus Conference 2019 provided consensus
guidance and developed an implementation framework regarding
germline testing for PCa [5]. The conference emphasized the need for
urology and oncology practices to consider models for germline PCa
testing [5]. However, current knowledge gaps and practice patterns
need to be identified for tailored strategies for germline testing.
A previous study by Paller et al. examined the uptake of germline
testing among academic medical oncologists at institutions in the
Prostate Cancer Clinical Trials Consortium (PCCTC) [6]. Among 26
respondents, 38% refer patients to a separate department for genetic
testing and counseling, and the remainder take personal responsibility
for some or all of genetic education and testing. Many of these academic
medical oncologists (62%) consider germline testing for all patients
with metastatic PCa, while others also consider family history in those
cases. Conversely, fewer participating oncologists consider germline
testing for men with high-risk localized PCa.
Although urologists are at the front lines of PCa diagnosis and
management, less is known to what extent genetic evaluation has been
incorporated into urological practice. Understanding the scope of
germline testing and gaps in knowledge and practice are important to
explore to inform responsible genetic evaluation and support provider
educational efforts. Our objective was to perform a more detailed as-
sessment of genetic knowledge and evaluation practices among U.S.
urologists in diverse practice settings to inform tailored PCa germline
testing education and implementation initiatives.
Materials and methods
An online survey was distributed by email through 6 American
Urological Association (AUA) sections (New York, Northeastern, North
Central, South Central, Southeastern and Western).
It was also sent via email to the Veterans Affairs Urology Mailgroup,
on the AUA Young Urologist Discussion forum, and in a Facebook group
of urologists. Distribution of the survey took place from October 2019-
March 2020.
The survey contained a total of 32 multiple-choice questions. Items
included demographics and practice type, using previously published
questions from the AUA Census [7]. The survey also included questions
on family history data collection, use of genetic counseling services and
germline testing. These included previously published questions from
the Advanced Prostate Cancer Consensus Conference [8]. Finally,
through consensus of the study team we created a series of case sce-
narios based upon the NCCN Guidelines where germline testing for men
with PCa is recommended or suggested [1,2].
Study data were collected and managed using REDCap electronic
data capture tools. REDCap (Research Electronic Data Capture) is a
secure, web-based platform supporting data capture for research [9,10].
Descriptive statistics were calculated using SAS. The chi-square test was
used to compare demographics and practice type between urologists
who refer to genetic counseling or perform germline testing, versus
those who do neither. Similar analyses were performed for the outcome
of recommending germline testing for patients with metastatic disease.
The study was approved by the NYU institutional review board.
Results
Practice results. Overall, the study included responses from 132 ur-
ologists from >25 states across the U.S. (Fig. 1), and reflected a broad
range of practice settings. Most respondents (58%) practice general
urology, with 31% specializing in PCa or urologic oncology. The
Fig. 1. Map showing in red the location of urologists who responded to the survey reflecting a wide geographic distribution across the U.S.**
**Not pictured are 9 respondents who listed their location as "other.".
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Table 1
Responses by urologists on germline testing for PCa patients*.
Question %
Respondent Demographics and Practice Information




















Community health center/HMO 1%
Other 4%











Practice Results Regarding Family History Collection, Germline Testing and
Management Implications
Do you ask prostate cancer patients if other family members have had the









I don't ask about family members' cancer 2%
If you ever recommend germline genetic testing, what do you test in men
with PCa?
I do not personally perform germline testing 54%
BRCA1 and BRCA2 testing only 3%
BRCA1, BRCA2 and ATM testing only 6%
Premade prostate cancer specific panels 7%
Large panel testing including homologous DNA repair 4%




Which of the following are important to discuss with patient prior to
making an informed decision for genetic testing? (Check all that
apply) (n = 129) (All are important to discuss)
Cancer inheritance (i.e., how mutations are passed in families) 58%
Risks, benefits, limitations of genetic testing 66%
Types of genetic test results and implications for management 43%
Genetic discrimination laws (GINA law) 26%
Reproductive implications (i.e., possible conditions in future children if
mutation)
30%
Genetic testing of relatives (cascade testing) 40%
None of the above 2%
N/A- I do not perform testing 23%
When do you recommend to start screening for men who are BRCA
carriers?
I do not recommend PCa screening 4%
I recommend PCa screening starting before age 40 16%
I recommend PCa screening starting at age 40 52%
Table 1 (continued)
Question %
I recommend PCa screening starting at age 45 15%
I recommend PCa screening starting at age 50 5%
I recommend PCa screening starting at age 55 1%
Abstain 6%
Other 1%
Does the presence of a germline BRCA1, BRCA2 or ATM mutation in men
with low-risk localized PCa influence your treatment decision?
Yes, I do not recommend active surveillance 27%
No, I discuss standard treatment options, including active surveillance 42%
Abstain 5%
Not qualified to answer 26%
Does the presence of a germline BRCA1, BRCA2 or ATM mutation in men
with intermediate or high-risk localized PCa influence your treatment
decision?
Yes I recommend radical prostatectomy over radiation therapy 24%
Yes, recommend radiation therapy over radical prostatectomy 2%
No, standard treatment recommendation 48%
Abstain 5%
Unqualified to answer 21%
Does the presence of a DNA repair defect in men with newly-diagnosed
metastatic castration-sensitive/naive prostate cancer influence your
upfront treatment decision for men with metastatic disease?
Yes, more likely to recommend Docetaxel to ADT 12%
Yes, include Platinum in the chemo-hormonal therapy 5%
Yes, other treatment recommendation 12%
Abstain 18%
Unqualified to answer 54%
Knowledge of PCa Genetics and Risk Assessment
Which of the following cancers may be connected to prostate cancer in
families? (n = 131) (Correct answers)
Breast Cancer (yes, through HBOC) 92%
Ovarian Cancer (yes, through HBOC or Lynch syndrome) 64%
Colorectal Cancer (yes, through Lynch syndrome) 38%
Pancreatic Cancer (yes, through HBOC or Lynch syndrome) 36%
Endometrial Cancer (Yes, through Lynch syndrome) 17%
Lung Cancer (not connected to PCa) 6%
Don't Know 5%
Which of the following tests evaluate some genes linked with hereditary
prostate cancer? (n = 130) (Correct answers)
Prolaris (No) 27%
Invitae Prostate Cancer Panel (Yes) 30%
Color Hereditary Cancer Testing (Yes) 27%
OncotypeDx (No) 29%
Myriad Genetics myRisk Hereditary Cancer Test (Yes) 58%
Decipher (No) 20%
Don't Know 16%
Which of the following genes have the strongest and consistent association











None of the above 0%
Don't know 19%
Which of the following genes are associated with aggressive or lethal
prostate cancer? (n = 131) (Yes=Optimal Choice)
BRCA1 49%
BRCA2 (Yes) 63%







None of the above 1%
Don't know 28%
⁎ Sample size for completed responses to each item is shown in the table.
Unanswered items were not included in the calculation of percentages. Number
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majority of participants see patients with advanced PCa sometimes
(30%), often (46%) or always (16%).
Table 1 shows the results. Virtually all participants (98%) ask about
family history of PCa, with most also obtaining information about re-
latives' age at diagnosis (93%), Gleason score (58%) and PCa death
(95%). Although 76% of respondents ask about family history of breast
cancer and 52% about ovarian cancer, a family history of other cancers
was asked by less than half of respondents. Most respondents indicated
interest in additional resources such as family history collection tools
for patients or education updates, and 38% were interested in a
smartphone app to refer patients for genetic evaluation.
Regarding germline testing, 12% perform germline testing in their
practice, 44% refer to a genetic counselor, and 11% do both.
Conversely, 33% do not perform testing or refer to a genetic counselor.
Respondents were presented with specific clinical scenarios in
which germline testing is indicated and whether they would refer such
a patient to a genetic counselor and/or perform testing (Table 2). A
majority of urologist respondents would refer/test men with metastatic
PCa with a family history of breast and ovarian cancer, or who have a
BRCA mutation on tumor profiling. Fewer would refer/test patients
with high-risk PCa who do not have a family history, or patients with
low or very low-risk disease who meet criteria. Overall, only 2% of
respondents answered correctly for all 11 case scenarios that are re-
commended in the NCCN guidelines. A total of 26% would refer or test
for all 3 metastatic case scenarios, and 3% would refer or test for all 8
non-metastatic case scenarios.
In terms of additional barriers to optimal implementation, only 55%
of respondents reported that they have access to a genetic counselor;
however, a considerable proportion of urologists who perform germline
testing do not discuss key topics such as genetic discrimination laws,
reproductive implications, or testing of other relatives (Table 1). In the
minority of participants who perform germline testing, there were
mixed responses regarding the number of genes that should be tested
(e.g. large panel versus PCa-specific panel versus BRCA1/2 and ATM
testing only).
Urologists were asked how germline test results influence practice
(Table 1). Only 30% of urologist respondents reported that germline
results affect their PCa screening recommendations. The most common
age to start screening was 40 for BRCA carriers (52%), while 16% re-
commend screening before age 40 in BRCA mutation carriers. Current
NCCN guidelines recommend starting PCa screening at age 40 for
BRCA2 carriers and to consider the same for BRCA1 carriers [1]. For
men with low-risk localized disease, 27% do include BRCA2 mutation
results in active surveillance discussions, which is advocated in the
NCCN Prostate Cancer guideline [2]. For newly diagnosed metastatic
castration-sensitive PCa, most participants felt unqualified to answer
whether DNA repair defects influence upfront management decisions.
Knowledge results. Regarding knowledge of germline testing for PCa,
there was variability noted. Most urologist respondents are aware that
breast cancer (92%) and ovarian cancer (64%) may be connected to
PCa in families, but less than 40% were aware of a link to other cancers
such as pancreatic, colorectal, or endometrial cancer suggestive of
Lynch syndrome.
Although most urologists who responded to the survey use genomic
tests in their practice (most commonly OncotypeDx, used by 60%), one-
third were not confident in explaining genomic versus germline genetic
testing. Approximately 25% of participants incorrectly indicated that
genomic tests such as OncotypeDx and Prolaris evaluate some genes
linked with hereditary cancer risk.
In terms of specific genes, 78% and 62% of respondents were aware
of an association between BRCA2 and BRCA1, respectively, with in-
herited PCa risk; further, 63% of respondents reported an association
between BRCA2 and aggressive or lethal PCa. A minority of respondents
were aware of a link between HOXB13 with inherited PCa risk, where
there is strong association.
Predictors of germline PCa testing. Table 3a and b show factors as-
sociated with the performance or consideration of germline PCa testing
in urology practice. As shown in Table 3a, younger urologists
(p = 0,03), those in academic practice (p = 0.04), and who specialize
in PCa or oncology (p = 0.007) were significantly more likely to per-
form or refer patients for germline testing compared to those who did
neither. Specializing in PCa or urologic oncology was significantly as-
sociated with recommending germline testing for all case scenarios
from Table 2 involving patients with metastatic PCa (p = 0.0009)
(Table 3b).
Discussion
Our nationwide survey of US urologists indicated a spectrum of
practice regarding PCa germline testing, with nearly half referring to
genetic counseling. A growing minority are performing germline PCa
testing within their practices. However, gaps in family history
of blank answers per question ranged from 0 to 11 with a median of 4.
Table 2
Germline testing of men with prostate cancer based on specific clinical scenarios as indicated by NCCN guidelines) [1,2].*.
For each type of patient scenario below, please indicate if you perform or refer them for germline testing
(n = 120–126):
Yes (refer or perform) No Don't assess
Guidelines: Testing is clinically indicated for metastatic prostate cancer at any age.
Metastatic prostate cancer, mother with breast cancer, sister with ovarian cancer 65% 14% 21%
Metastatic prostate cancer, no family history of malignancy 31% 44% 25%
Metastatic prostate cancer, BRCA mutation in tumor profiling 63% 14% 22%
Guideline: Germline testing is recommended for high-risk localized prostate cancer (T3a OR Grade Group 4 or 5, OR PSA >20 ng/ml).
High-risk localized prostate cancer (Gleason 10), no family history of malignancy 40% 39% 21%
Guideline: Testing is clinically indicated for high-grade (Gleason score ≥7) prostate cancer with ≥1 close blood relative with metastatic prostate cancer at any age.
High-risk localized prostate cancer (Gleason 10), brother died from prostate cancer 68% 19% 14%
Guideline: Testing is clinically indicated for high-grade (Gleason score ≥7) prostate cancer with Ashkenazi Jewish ancestry.
High-risk localized prostate cancer, Ashkenazi Jewish ancestry, no family history of malignancy 50% 28% 21%
Intermediate-risk localized prostate cancer, Ashkenazi Jewish ancestry, no family history of malignancy 28% 45% 27%
Low-risk prostate cancer, Ashkenazi Jewish ancestry, no family history of malignancy 14% 58% 28%
Guideline: Testing is clinically indicated for individuals with a first or second degree blood relative with ≥1 close blood relative with breast, ovarian, pancreatic or high-grade
(Gleason score ≥7) or intraductal prostate cancer at any age.
Low-risk localized prostate cancer, mom and sister with breast cancer, maternal uncle with colorectal cancer 58% 23% 19%
Guideline: Testing is clinically indicated for individuals with any blood relative with a known pathogenic variant in a cancer susceptibility gene.
Low-risk prostate cancer, mom with BRCA mutation 52% 27% 22%
Guideline: Testing is clinically indicated for intraductal prostate cancer at any age.
Very low-risk localized prostate cancer with intraductal histology, no family history of malignancy 12% 60% 27%
⁎ Each of these scenarios would meet current criteria for germline PCa testing.
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collection and knowledge were identified that need to be addressed for
responsible implementation of PCa germline testing
To date, very few studies have examined family history data col-
lection or use of genetic testing among urologists. A 2014 survey of 87
members of the Chicago Urological Society reported that 95% of urol-
ogists always obtained family history when discussing PCa risk and
87% when discussing screening options [11]. However, only 57% al-
ways obtained family history when discussing treatment options, pri-
marily due to the belief that it would not change management. Our
results show that while virtually all urologists collect data on family
history of PCa, many do not ask about history of cancer in female re-
latives or other tumor types with genetic links to PCa. Broad family
history collection is very important for optimal testing and genetic as-
sessment, which encompasses genes linked with hereditary cancer
syndromes.
A more recent survey of 52 large U.S. urology group practices re-
ported that 63% were already offering testing to selected patients [12].
However, barriers to testing included concerns of medico-legal liability,
reimbursement, and difficulty collecting detailed family history in the
medical record. Our study expands upon these results by examining
practice patterns in multiple practice settings and specific clinical sce-
narios. We found additional barriers in terms of specific knowledge
gaps and preferences for additional resources, which are actionable
results. In addition, we found that many urologists lack access to a
genetic counselor, which might be improved in the future through the
use of telemedicine or other technology-based solutions.
Finally, a 2017 survey of 691 providers reported that 26% of urol-
ogists and 4% of radiation oncologists frequently used "genetic
tests."[13] The most commonly employed tests were Prolaris and On-
cotype, neither of which captures germline genetic variants and are
more appropriately classified as “genomic tests”. Indeed, the use of
genomic tests may be much more familiar in urologic practice com-
pared to germline testing. In the 2019 American Urological Association
census, 59% of U.S. urologists reported using genomic tests to help
stratify patients with PCa for active surveillance, which corroborates
our findings in this survey [7]. Despite the widespread use of genomic
tests, more than 1/4 of respondents in our survey believed that the
Prolaris, Oncotype and/or Decipher tests evaluate genes linked with
hereditary PCa. Our findings highlight the need for decision support
tools or additional targeted education on PCa genetics, indications for
germline testing and types of testing options.
In terms of screening recommendations, most urologists recommend
screening starting at 40 for men with BRCA mutations. These are in line
with current NCCN guidelines for Prostate Cancer Early Detection. Data
from the IMPACT study suggested that targeted screening in BRCA
mutation carriers detects a high proportion of clinically significant
disease [14]. Similarly the American Urological Association Guidelines
state that certain subgroups of men age 40 to 54 years may realize
added benefit from earlier screening, including those with a family
history of metastatic or lethal adenocarcinomas (e.g., prostate, male
and female breast cancer, ovarian, pancreatic) spanning multiple gen-
erations, affecting multiple first-degree relatives, and that developed at
younger ages.
With regard to PCa treatment, a minority of urologist respondents
currently alter their management decisions based on germline results.
For men with low-risk localized disease, 27% do not recommend active
surveillance in the presence of a BRCA2 mutation. However, to date the
main evidence on active surveillance is from a study by Carter et al.
showing a significantly higher risk of grade reclassification among men
with mutations in a 3 gene panel including BRCA1, BRCA2, and ATM
[15]. Since these data are very early and based on a small sample size, it
is possible that many urologists and/or patients do not find the strength
of underlying evidence sufficient to alter practice patterns. Meanwhile,
for men with intermediate or high-risk localized PCa, 24% would re-
commend prostatectomy over radiation therapy, despite no data in
support of specific modalities of local therapy based on mutation status.
Compared to previous data from academic medical oncologists[6],
the proportion of urologists who are comfortable performing germline
testing is substantially lower. Possible reasons for these differences may
include differential training and experience with germline testing in
other patient contexts, and the extent to which germline results impact
management decisions in advanced versus localized PCa. That not-
withstanding, with most urologists reporting that they manage ad-
vanced PCa, and the 2020 American Urological Association guidelines
recommend that clinicians should offer a PARP inhibitor to patients
with deleterious or suspected deleterious germline or somatic homo-
logous recombination repair gene-mutated mCRPC following prior
treatment with enzalutamide or abiraterone acetate, and/or a taxane-
based chemotherapy. They also recommend offering pembrolizumab
for patients with mismatch repair deficient or microsatellite instability
high metastatic CRPC. Therefore, greater integration of genetic coun-
seling models to facilitate germline testing into urological care is im-
portant at multiple points of patient care, in addition to implications for
family members. Further qualitative research is warranted to define the
barriers and facilitators to implementation of germline testing in ur-
ological practice. Future interventions should address urologists in the
groups who are less likely to refer patients or perform testing (e.g.,
older age, non-academic, and those who do not specialize in PCa/on-
cology).
A limitation of the study is the low response rate, which is common
in urological survey research [16]. According to the 2019 AUA census,
there are 13,044 practicing urologists in the U.S. [7] At the time of
distribution, the email and social media groups that we used to send out
the survey included 13,363 total people; however not everyone on the
Table 3
Utilization of germline testing/counseling (a) in general and (b) for patients
with metastatic prostate cancer by demographic and practice characteristics.
a) General utilization of germline testing/counseling













Frequency of Advanced PCa
Often/Always 69% 0.45
Less Frequently 63%
b) Utilization of germline testing/counseling for patients with metastatic prostate
cancer















Frequency of Advanced PCa
Often/Always 26% 0.96
Less Frequently 25%
S. Loeb, et al. Cancer Treatment and Research Communications 25 (2020) 100212
5
AUA section email lists is a practicing urologist eligible for the survey,
and there is overlap between the AUA sections with the VA mailgroup
and social media groups. Despite the use of several different distribu-
tion methods, our sample represents <1% of U.S. urologists. This limits
the generalizability of our findings to the full landscape of urology
practice in the U.S. Compared to data from the AUA census, our survey
included fewer urologists with <25 years in practice (50% vs 59%),
fewer in private practice (45% vs 53%), and specializing in general
urology (58% vs 60%). Additional demographic data for providers (e.g.,
gender and race/ethnicity) were not asked in the survey. Also, re-
sponses about the frequency of seeing patients with metastatic prostate
cancer are subjective and we do not have objective clinical data to
examine this or utilization of precision therapy in clinical practice.
Another limitation of the study is that the reported percent of ur-
ologists who perform germline testing may be an overestimate, since
approximately 1/3 of respondents were uncertain about the difference
between genomic versus germline testing. In addition, our survey did
not ask about additional potential barriers to germline testing (e.g.,
reimbursement issues, organizational factors) that might influence
testing patterns. Also, there is some variability in guidelines across
NCCN panels and some of the testing criteria are based on expert opi-
nion, which may have influenced responses to the case scenarios.
Additional qualitative work is important to follow up on these findings
and explore the factors that influence uptake of genetic evaluation in
practice.
Strengths of our study include sampling from a geographically di-
verse sample of urologists from diverse practice settings across the U.S.
Our study included very detailed information on family history col-
lection and case-based use of germline testing, which provide an im-
portant snapshot into current patterns of care with respect to germline
genetic evaluation in urological practice. On the basis of participant
responses, several key gaps or barriers were identified with proposed
solutions to better operationalize PCa germline testing in urology
practice. These data highlight numerous gaps for future research (e.g.,
barriers and facilitators to germline genetic evaluation) as well as ac-
tionable findings to promote guideline-concordant care, including new
opportunities for continuing education for urologists about genetic risk
assessment and decision support tools to aid in clinical decision-making
regarding germline evaluation.
Conclusions
Given the substantial implications of genetic testing for patients and
their families, it is essential that urologists have the education and
practice resources to responsibly implement genetic assessment in
clinical practice. Although most urologists manage patients with ad-
vanced PCa, 1/3 of urologists neither refer patients to genetic coun-
seling nor perform germline testing in their practice. Our survey has
identified numerous actionable gaps, which will inform future research
on how to optimize the implementation of genetic evaluation into ur-
ological care.
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